Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection (NOCOVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04337918
Recruitment Status : Recruiting
First Posted : April 8, 2020
Last Update Posted : May 12, 2020
Sponsor:
Collaborator:
The Emmes Company, LLC
Information provided by (Responsible Party):
Sanotize Research and Development corp.

Brief Summary:
This is a multi-center, randomized, controlled, phase II clinical efficacy study evaluating a novel Nitric Oxide Releasing Solution (NORS) treatment for the prevention and treatment of COVID-19 in healthcare workers at risk of infection. Participants will be enrolled into one of two components of this study. Based on initial swabs/symptoms, volunteers who are COVID-19 negative will be enrolled in the Prevention study and randomized to receive standard institutional precautions or standard institutional precautions + NORS. Those who are COVID-19 positive will be enrolled in the open-label Treatment Sub-Study.

Condition or disease Intervention/treatment Phase
Corona Virus Infection Drug: NORS (Nitric Oxide Releasing Solution) Phase 2

Detailed Description:

The novel, human-infecting corona-virus, provisionally named 2019 novel corona virus (2019-nCoV) is a single-strand, positive-sense RNA virus and has a similar receptor-binding domain structure to that of SARS-CoV and MERS-CoV. The virus is transmitted via airborne droplets to the nasal mucosa. Replication occurs locally in the nasal mucosa, in ciliated epithelial cells, over a 3-day incubation period. The mucosal cells are damaged with a resultant inflammatory response similar to the common cold. During this time the virus is shed in nasal secretions causing disease in the lower respiratory tract, potentially causing fatal viral pneumonia.

The literature supports that NO or its derivatives have inhibitory effects on a variety of viral infections. This inhibitory effect was shown to be marked in Interferon (IFN) mediated inhibition manifested by activated macrophage. It was also shown to be correlated with s-nitrosylation of viral proteins such as reductases and proteases.

Based on the genetic similarities between SARS and corona viruses, similar viricidal effects of NO on COVID-19 can be hypothesized.

SaNOtize has developed an innovative approach to provide nitric oxide gas using a formulation called Nitric Oxide Releasing Solution (NORS). This patented solution releases virucidal doses of NO for a sustained period and is effective at rapidly inactivating Influenza A and SARS-CoV-2.

NORS delivered as a gargle (AM), nasal spray (PRN) or as a nasopharyngeal flush (PM) has the potential to decontaminate the upper respiratory tract that could preventing transmission and progression of COVID-19 in Healthcare Workers & Individuals at Risk of Infection.

The randomized Prevention study will investigate the ability of NORS to prevent COVID-19 infection when used prophylactically. The open-label Treatment Sub-Study is expected to be small and will provide pilot data on the possibility of NORS as a treatment for Mild/Moderate COVID-19 infection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-center, prospective, randomized, controlled, phase II, parallel group
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection
Actual Study Start Date : May 8, 2020
Estimated Primary Completion Date : July 31, 2020
Estimated Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Prevention - Standard Precautions
Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols).
Experimental: Prevention - NORS + Standard Precautions
Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols) plus daily NORS treatment for 14 days.
Drug: NORS (Nitric Oxide Releasing Solution)
NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
Other Name: NOG, NONI, NONS

Treatment Sub-Study

Volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. Ten participants can be directly enrolled in the Treatment sub-study.

Participants enrolled in the Prevention study who meet the criteria in this section will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.

Drug: NORS (Nitric Oxide Releasing Solution)

Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.

Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.

Other Name: NOG, NONI, NONS




Primary Outcome Measures :
  1. Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19 [ Time Frame: 14 days ]
    Measure the proportion of subjects with either swab positive COVID-19 or presentation of clinical symptoms as measured by fatigue with either fever >37.2 (oral)and/or a persistent cough.

  2. Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19 [ Time Frame: 21 days ]
    Measure the proportion of participants requiring requiring hospitalization for COVID-19/flu-like symptoms and/or needing oxygen therapy, BIPAP/CPAP, intubation and mechanical ventilation following enrollment.


Secondary Outcome Measures :
  1. Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19 [ Time Frame: 21 days ]
    Measure the proportion of participants requiring requiring hospitalization for COVID-19/flu-like symptoms and/or needing oxygen therapy, BIPAP/CPAP, intubation and mechanical ventilation following enrollment.

  2. Prevention Study: Measure the tolerability of NORS treatments [ Time Frame: 21 days ]
    Measure the tolerability of the NORS treatments as determined by number of adverse events, pain, discomfort or discontinuations of treatment.

  3. Treatment Sub Study: Measure the virucidal effect of NORS Treatments [ Time Frame: 21 days ]
    Measure the median number of days to negative conversion of SARS-CoV-2 RT-PCR from a nasopharyngeal swabs.

  4. Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery [ Time Frame: 21 days ]
    Determine the time to clinical recovery in participants with COVID-19 by measuring the median number of days from enrollment to discharge (if admitted), or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air).

  5. Treatment Sub Study: Determine the reduction in clinical symptoms [ Time Frame: 21 days ]
    Measure the reduction clinical symptoms in participants with COVID- 19 by the magnitude of the change in Modified Jackson Cold Score Diary Score (5-unit change is a substantial clinical benefit).

  6. Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2 [ Time Frame: 21 days ]
    Measure the proportion of participants that have a positive sero-conversion for SARS-CoV-2



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Prevention Study Inclusion Criteria:

  1. Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol;
  2. Men and Women ≥ 19 years of age unless local laws dictate otherwise;
  3. English speaking;
  4. Must be willing to use an adequate form of contraception (or abstinence) from the time of the first dose with the IMP until after the last dose of IMP.
  5. Be symptom-free at screening/baseline.
  6. Work/live in contact with COVID-19 infected patients or scheduled to work in a setting with high likelihood of contact with COVID-19 infected patients.

Prevention Study Exclusion Criteria:

  1. Prior Tracheostomy;
  2. Concomitant treatment of respiratory support (involving any form of oxygen therapy);
  3. Any clinical contraindications, as judged by the attending physician;
  4. Any symptoms consistent with COVID-19;
  5. Pregnant;
  6. Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study;
  7. Prior COVID-19 infection.

Treatment Sub study Inclusion Criteria:

  1. Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol;
  2. Men and Women ≥ 19 years of age unless local laws dictate otherwise;
  3. English speaking;
  4. Must be willing to use an adequate form of contraception (or abstinence) from the time of the first dose with the IMP until after the last dose of IMP;
  5. Positive COVID-19 test or presentation of clinical symptoms defined as fatigue with either fever >37.2 (oral) and/or a persistent cough.

Treatment Sub Study Exclusion Criteria:

  1. Prior Tracheostomy;
  2. Concomitant treatment of respiratory support (involving any form of oxygen therapy); Any clinical contraindications, as judged by the attending physician;
  3. Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study;
  4. Pregnant;
  5. Currently hospitalized for symptoms of COVID-19.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04337918


Contacts
Layout table for location contacts
Contact: Chris Miller, Ph.D. 778-899-0607 chris@sanotize.com
Contact: Gilly Regev, Ph.D. 604-727-3014

Locations
Layout table for location information
Canada, British Columbia
BC Diabetes Recruiting
Vancouver, British Columbia, Canada, V5Y 3W2
Contact: Ali Moshiri, MD    604-628-2395    nors@bcdiabetes.ca   
Contact: Praveen Samuel, MD    604-628-2395    nors@bcdiabetes.ca   
Sponsors and Collaborators
Sanotize Research and Development corp.
The Emmes Company, LLC
Investigators
Layout table for investigator information
Principal Investigator: Jeremy Road, MD Private Practice
Publications:

Layout table for additonal information
Responsible Party: Sanotize Research and Development corp.
ClinicalTrials.gov Identifier: NCT04337918    
Other Study ID Numbers: COVID-CTP-01
First Posted: April 8, 2020    Key Record Dates
Last Update Posted: May 12, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sanotize Research and Development corp.:
Antiviral
Virucidal
Nitric Oxide
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Coronavirus Infections
Severe Acute Respiratory Syndrome
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Respiratory Tract Infections
Respiratory Tract Diseases
Nitric Oxide
Pharmaceutical Solutions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents